Skip to main content

Table 3 Three-year conditional survival rates of patients with primary retroperitoneal tumors after surgical resection in relation to prognostic factors

From: Conditional survival after surgical resection of primary retroperitoneal tumors: a population-based study

Variable COS3, % CCSS3, %
Years since diagnosis Years since diagnosis
Basline 1y 2y 3y 4y 5y Basline 1y 2y 3y 4y 5y
Overall 71.8 72.9 76.5 77.9 79.6 79.3 77.1 78.1 81.3 82.7 84.9 85.8
Age (year)
 < 65 75.8 76.3 78.9 82.1 84.1 83.3 79.0 79.8 81.7 84.8 87.6 88.6
 ≥ 65 65.5 66.9 71.9 69.5 70.3 70.5 73.9 75.0 80.6 78.4 79.1 79.6
d (< 65 vs. ≥ 65) 0.23 0.21 0.17 0.31 0.35 0.31 0.12 0.12 0.03 0.16 0.24 0.26
Sex
Male 69.5 73.6 76.2 76.2 76.8 75.5 75.1 79.5 81.7 81.7 82.1 83.9
Female 73.8 72.3 76.7 79.3 81.9 82.3 78.7 76.9 85.0 83.4 87.2 87.3
d (male vs. female) − 0.10 0.03 − 0.01 − 0.08 − 0.13 − 0.17 − 0.09 0.06 − 0.08 − 0.04 − 0.14 − 0.10
Marital status
Married 73.3 76.6 79.8 79.6 78.9 79.6       
Unmarried 71.9 70.9 74.8 81.0 82.8 79.4       
Unknown 67.8 64.1 68.6 70.7 79.8 78.0       
d (married vs. unmarried) 0.03 0.13 0.12 − 0.03 − 0.09 0.0       
d (married vs. unknown) 0.12 0.28 0.26 0.21 − 0.02 − 0.02 0.11 0.11 0.24 0.17 − 0.11 − 0.07
FNCLCC grade
I 90.5 87.7 87.1 89.1 85.4 90.0 93.0 93.4 92.9 94.4 94.4 98.2
II 75.6 69.9 65.7 71.8 83.5 94.4 82.8 74.7 69.4 76.0 88.4 100.0
III 53.8 58.5 66.2 68.0 71.5 78.9 61.2 65.8 72.0 72.0 74.1 81.7
Unknown 72.7 73.6 77.4 77.8 79.7 79.1 77.6 78.2 81.7 82.6 85.3 85.6
d (I vs. II) 0.33 0.40 0.50 0.42 0.05 − 0.11 0.24 0.46 0.60 0.49 0.17 − 0.05
d (I vs. III) 0.82 0.65 0.50 0.51 0.35 0.27 0.76 0.67 0.54 0.59 0.56 0.47
d (I vs. Unknown) 0.40 0.32 0.23 0.27 0.14 0.66 0.37 0.37 0.29 0.31 0.25 0.36
Size (cm)
 < 5 84.8 80.9 87.0 87.3 75.1 71.8 90.9 86.4 91.7 89.1 75.1 71.8
5–10 75.4 75.9 79.0 82.1 88.1 90.4 80.6 80.8 82.9 85.5 89.5 92.4
10–15 72.5 69.0 75.4 78.3 80.6 80.6 78.6 75.5 80.5 82.9 86.4 87.3
 ≥ 15 69.0 72.6 75.6 76.6 77.2 76.7 74 77.3 80.5 81.5 83.5 84.6
Unknown 74.1 66.9 67.5 61.0 66.9 57.2 79.5 73.8 74.6 74.1 83.7 74.8
d (< 5 vs. 5–10) 0.21 0.11 0.19 0.13 − 0.33 − 0.45 0.25 0.14 0.23 0.09 − 0.40 − 0.59
d (< 5 vs. 10–15) 0.27 0.26 0.28 0.22 0.14 − 0.21 0.29 0.27 0.29 0.16 − 0.31 − 0.44
d (< 5 vs. ≥ 15) 0.35 0.18 0.27 0.26 0.05 − 0.12 0.40 0.22 0.29 0.20 − 0.23 − 0.37
d (< 5 vs. Unknown) 0.24 0.32 0.46 0.63 0.20 0.89 0.27 0.30 0.44 0.40 − 0.24 − 0.09
Multifocality
No 69.7 70.4 74.7 76.7 79.6 79.1 73.6 74.2 77.8 79.5 87.1 83.1
Yes 84.1 85.6 84.6 82.9 79.6 79.7 97.5 98.4 97.5 95.9 94.7 96.0
d (No vs. Yes) − 0.32 − 0.34 − 0.24 − 0.15 0 − 0.01 − 0.57 − 0.59 − 0.51 − 0.43 − 0.21 − 0.37
Histology
SFT 86.7 86.7 88.9 88.9 76.2 68.6 86.7 86.7 88.9 88.9 76.2 68.6
MFHC 41.7 56.0 66.7 80.0 64.3 50.0 49.2 62.0 70.6 80 71.4 64.8
MPNST 62.3 63.5 71.4 55.6 66.7 66.7 76.2 76.2 85.7 100.0 100.0 100.0
LMS 70.2 67.4 71.6 73.4 79.6 84.1 75.6 72.6 75.6 75.7 81.6 85.7
DD lipo 63.6 65.8 66.6 66.7 66.5 68.2 68.7 70.7 72.4 72.3 74.2 76.9
WD lipo 90.4 88.0 88.5 86.3 88.2 86.3 95.6 93.8 94.2 91.7 92.4 91.7
Other 67.9 71.3 77.5 81.0 82.2 80.1 72.7 76.1 81.5 86.4 88.9 88.7
d (SFT vs. MFHC) 1.00 0.68 0.53 0.22 0.30 0.45 0.89 0.60 0.47 0.23 0.13 0.11
d (SFT vs. MPNST) 0.54 0.52 0.42 0.81 0.24 0.05 0.25 0.26 0.08 − 0.29 − 0.66 − 0.90
d (SFT vs. LMS) 0.37 0.43 0.41 0.38 − 0.09 − 0.38 0.26 0.34 0.34 0.35 − 0.15 − 0.49
d (SFT vs. DD lipo) 0.51 0.46 0.53 0.54 0.24 0.01 0.43 0.39 0.42 0.44 0.06 − 0.24
d (SFT vs. WD lipo) − 0.08 − 0.03 0.01 0.06 − 0.30 − 0.43 − 0.21 − 0.17 − 0.14 − 0.07 − 0.45 − 0.66
d (SFT vs. Other) 0.42 0.34 0.27 0.19 − 0.15 − 0.28 0.33 0.26 0.19 0.07 − 0.35 − 0.57
Chemotherapy
No 74.9 75.9 78.8 79.8 81.3 80.2 80.6 81.3 83.8 84.5 86.5 86.7
Yes 53.8 53.9 60.6 63.2 66.2 71.2 56.2 58.0 64.1 68.6 72.2 77.7
d (No vs. Yes) 0.47 0.49 0.43 0.40 0.38 0.22 0.58 0.57 0.51 0.42 0.40 0.26
  1. SFT solitary fibrous tumor, MFHC Malignant fibrous histiocytoma, MPNST malignant peripheral nerve sheath tumor, LMS leiomyosarcoma, DD lipo dedifferentiated liposarcoma, WD lipo well-differentiated liposarcoma, FNCLCC French National Federation of the Centers for the Fight Against Cancer, API Asian/Pacific Islander, COS3 3-year conditional overall survival, CCSS3 3-year conditional cancer-specific survival, y year, d standardized difference